Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy

Autophagy

Volumn 11, Issue 10, 2015, Pages 1711-1728

  Yu, Xinlei ^a   Long, Yun Chau ^a   Shen, Han Ming ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHAGY PROTEIN 14; BECLIN 1; MULTIPROTEIN COMPLEX; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN; UNCLASSIFIED DRUG; UVRAG PROTEIN; APOPTOSIS REGULATORY PROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTOPHAGY; ENZYME ACTIVITY; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PROCESSING; REGULATORY MECHANISM; ANIMAL; METABOLISM; PHAGOSOME; PHYSIOLOGY;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CLASS III PHOSPHATIDYLINOSITOL 3-KINASES; HUMANS; MULTIPROTEIN COMPLEXES; PHAGOSOMES; PHOSPHATIDYLINOSITOLS; TOR SERINE-THREONINE KINASES;

EID: 84953866121     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.1080/15548627.2015.1043076     Document Type: Article

References (252)

1. Mizushima N. Autophagy: process and function. Genes Dev 2007; 21:2861-73; PMID:18006683; http://dx.doi.org/10.1101/gad.1599207
2. Yamada E, Singh R.Mapping autophagy on to your metabolic radar. Diabetes 2012; 61:272-80; PMID:22275084; http://dx.doi.org/10.2337/db11-1199
3. Singh R, Cuervo AM. Autophagy in the cellular energetic balance. Cell Metab 2011; 13:495-504; PMID:21531332; http://dx.doi.org/10.1016/j.cmet.2011.04.004
4. Shen HM, Codogno P. Autophagic cell death: Loch Ness monster or endangered species? Autophagy 2011; 7:457-65; PMID:21150268; http://dx.doi.org/10.4161/auto.7.5.14226
5. Tanida I. Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal 2011; 14:2201-14; PMID:20712405; http://dx.doi.org/10.1089/ars.2010.3482
6. Shibutani ST, Yoshimori T. A current perspective of autophagosome biogenesis. Cell Res 2014; 24:58-68; PMID:24296784; http://dx.doi.org/10.1038/cr.2013.159
7. Simonsen A, Tooze SA. Coordination of membrane events during autophagy by multiple class III PI3- kinase complexes. J Cell Biol 2009; 186:773-82; PMID:19797076; http://dx.doi.org/10.1083/jcb.200907014
8. Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y. Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol 2009; 10:458-67; PMID:19491929; http://dx.doi.org/10.1038/nrm2708
9. Carlsson SR, Simonsen A. Membrane dynamics in autophagosome biogenesis. J Cell Sci 2015; 128:193-205; PMID:25568151; http://dx.doi.org/10.1242/jcs.141036
10. Suzuki K, Ohsumi Y. Current knowledge of the preautophagosomal structure (PAS). FEBS Lett 2010; 584:1280-6; PMID:20138172; http://dx.doi.org/10.1016/j.febslet.2010.02.001
11. Itakura E, Mizushima N. Characterization of autophagosome formation site by a hierarchical analysis of mammalian Atg proteins. Autophagy 2010; 6:764-76; PMID:20639694; http://dx.doi.org/10.4161/auto.6.6.12709
12. Karanasios E, Stapleton E, Manifava M, Kaizuka T, Mizushima N, Walker SA, Ktistakis NT. Dynamic association of the ULK1 complex with omegasomes during autophagy induction. J Cell Sci 2013; 126:5224-38; PMID:24013547; http://dx.doi.org/10.1242/jcs.132415
13. Wirth M, Joachim J, Tooze SA. Autophagosome formation– the role of ULK1 and Beclin1-PI3KC3 complexes in setting the stage. Semin Cancer Biol 2013; 23:301-9; PMID:23727157; http://dx.doi.org/10.1016/j.semcancer.2013.05.007
14. Russell RC, Yuan HX, Guan KL. Autophagy regulation by nutrient signaling. Cell Res 2014; 24:42-57; PMID:24343578; http://dx.doi.org/10.1038/cr.2013.166
15. Koyama-Honda I, Itakura E, Fujiwara TK, Mizushima N. Temporal analysis of recruitment of mammalian ATG proteins to the autophagosome formation site. Autophagy 2013; 9:1491-9; PMID:23884233; http://dx.doi.org/10.4161/auto.25529
16. Axe EL, Walker SA, Manifava M, Chandra P, Roderick HL, Habermann A, Griffiths G, Ktistakis NT. Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. J Cell Biol 2008; 182:685-701; PMID:18725538; http://dx.doi.org/10.1083/jcb.200803137
17. Dall’Armi C, Devereaux KA, Di Paolo G. The role of lipids in the control of autophagy. Curr Biol 2013; 23:R33-45; PMID:23305670; http://dx.doi.org/10.1016/j.cub.2012.10.041
18. Xie Z, Nair U, Klionsky DJ. Atg8 controls phagophore expansion during autophagosome formation. Mol Biol Cell 2008; 19:3290-8; PMID:18508918; http://dx.doi.org/10.1091/mbc.E07-12-1292
19. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011; 7:279-96; PMID:21189453; http://dx.doi.org/10.4161/auto.7.3.14487
20. Suzuki K, Akioka M, Kondo-Kakuta C, Yamamoto H, Ohsumi Y. Fine mapping of autophagy-related proteins during autophagosome formation in Saccharomyces cerevisiae. J Cell Sci 2013; 126:2534-44; PMID:23549786; http://dx.doi.org/10.1242/jcs.122960
21. Orsi A, Razi M, Dooley HC, Robinson D, Weston AE, Collinson LM, Tooze SA. Dynamic and transie interactions of Atg9 with autophagosomes, but not membrane integration, are required for autophagy. Mol Biol Cell 2012; 23:1860-73; PMID:22456507; http://dx.doi.org/10.1091/mbc.E11-09-0746
22. Young AR, Chan EY, Hu XW, Kochl R, Crawshaw SG, High S, Hailey DW, Lippincott-Schwartz J, Tooze SA. Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. J Cell Sci 2006; 119:3888-900; PMID:16940348; http://dx.doi.org/10.1242/jcs.03172
23. Shen HM, Mizushima N. At the end of the autophagic road: an emerging understanding of lysosomal functions in autophagy. Trends Biochem Sci 2014; 39:61-71; PMID:24369758; http://dx.doi.org/10.1016/j.tibs.2013.12.001
24. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol 2013; 6:88; PMID:24261963; http://dx.doi.org/10.1186/1756-8722-6-88
25. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoformspecific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11:329-41; PMID:20379207; http://dx.doi.org/10.1038/nrm2882
26. McNamara CR, Degterev A. Small-molecule inhibitors of the PI3K signaling network. Fut Med Chem 2011; 3:549-65; PMID:21526896; http://dx.doi.org/10.4155/fmc.11.12
27. O Farrell F, Rusten TE, Stenmark H. Phosphoinositide 3-kinases as accelerators and brakes of autophagy. FEBS J 2013; 280:6322-37; PMID:23953235; http://dx.doi.org/10.1111/febs.12486
28. Foster FM, Traer CJ, Abraham SM, Fry MJ. The phosphoinositide (PI) 3-kinase family. J Cell Sci 2003; 116:3037-40; PMID:12829733; http://dx.doi.org/10.1242/jcs.00609
29. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-44; PMID:19644473; http://dx.doi.org/10.1038/nrd2926
30. Durocher D, Jackson SP. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 2001; 13:225-31; PMID:11248557; http://dx.doi.org/10.1016/S0955-0674(00)00201-5
31. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005; 434:605-11; PMID:15758953; http://dx.doi.org/10.1038/nature03442
32. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461:1071-8; PMID:19847258; http://dx.doi.org/10.1038/nature08467
33. Chen JH, Zhang P, Chen WD, Li DD, Wu XQ, Deng R, Jiao L, Li X, Ji J, Feng GK, et al. ATMmediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells. Autophagy 2015; 11:239-52; PMID: 25701194
34. Zou Y, Wang Q, Li B, Xie B, Wang W. Temozolomide induces autophagy via ATMAMPKULK1 pathways in glioma. Mol Med Rep 2014; 10:411-6; PMID: 24737504
35. Liang N, Jia L, Liu Y, Liang B, Kong D, Yan M, Ma S, Liu X. ATM pathway is essential for ionizing radiation- induced autophagy. Cell Signal 2013; 25:2530-9; PMID:23993957; http://dx.doi.org/10.1016/j.cellsig.2013.08.010
36. Tripathi DN, Chowdhury R, Trudel LJ, Tee AR, Slack RS, Walker CL, Wogan GN. Reactive nitrogen species regulate autophagy through ATM-AMPKTSC2- mediated suppression of mTORC1. Proc Natl Acad Sci U S A 2013; 110:E2950-7; PMID:23878245; http://dx.doi.org/10.1073/pnas.1307736110
37. Duan X, Ponomareva L, Veeranki S, Choubey D. IFI16 induction by glucose restriction in human fibroblasts contributes to autophagy through activation of the ATM/AMPK/p53 pathway. PloS One 2011; 6: e19532; PMID:21573174; http://dx.doi.org/10.1371/journal.pone.0019532
38. Zhuang W, Qin Z, Liang Z. The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim Biophys Sin 2009; 41:341-51; PMID:19430698; http://dx.doi.org/10.1093/abbs/gmp028
39. Vessoni AT, Filippi-Chiela EC, Menck CF, Lenz G. Autophagy and genomic integrity. Cell Death Differ 2013; 20:1444-54; PMID:23933813; http://dx.doi.org/10.1038/cdd.2013.103
40. Alexander A, Cai SL, Kim J, Nanez A, Sahin M, MacLean KH, Inoki K, Guan KL, Shen J, Person MD, et al. ATM signals to TSC2 in the cytoplasm to regulat emTORC1 in response to ROS. Proc Natl Acad Sci U SA 2010; 107:4153-8; PMID:20160076; http://dx.doi.org/10.1073/pnas.0913860107
41. Alexander A, Kim J, Walker CL. ATM engages the TSC2/mTORC1 signaling node to regulate autophagy. Autophagy 2010; 6:672-3; PMID:20581436; http://dx.doi.org/10.4161/auto.6.5.12509
42. Mori C, Yamaguchi Y, Teranishi M, Takanami T, Nagase T, Kanno S, Yasui A, Higashitani A. Overexpression of ATR causes autophagic cell death. Genes Cell 2013; 18:278-87; http://dx.doi.org/10.1111/gtc.12034
43. Daido S, Yamamoto A, Fujiwara K, Sawaya R, Kondo S, Kondo Y. Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy. Cancer Res 2005; 65:4368-75; PMID:15899829; http://dx.doi.org/10.1158/0008-5472.CAN-04-4202
44. Zhuang W, Li B, Long L, Chen L, Huang Q, Liang ZQ. Knockdown of the DNA-dependent protein kinase catalytic subunit radiosensitizes glioma-initiating cells by inducing autophagy. Brain Res 2011; 1371:7-15; PMID:21108935; http://dx.doi.org/10.1016/j.brainres.2010.11.044
45. Yoon JH, Ahn SG, Lee BH, Jung SH, Oh SH. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1. Biochem Pharmacol 2012; 83:747-57; PMID:22226932; http://dx.doi.org/10.1016/j.bcp.2011.12.029
46. Chen LH, Loong CC, Su TL, Lee YJ, Chu PM, Tsai ML, Tsai PH, Tu PH, Chi CW, Lee HC, et al. Autophagy inhibition enhances apoptosis triggered by BO-1051, an N-mustard derivative, and involves the ATM signaling pathway. Biochem Pharmacol 2011; 81:594-605; PMID:21184746; http://dx.doi.org/10.1016/j.bcp.2010.12.011
47. Zanotto-Filho A, Braganhol E, Klafke K, Figueiro F, Terra SR, Paludo FJ, Morrone M, Bristot IJ, Battastini AM, Forcelini CM, et al. Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. Cancer Lett 2015; 358:220-31; PMID:25542083; http://dx.doi.org/10.1016/j.canlet.2014.12.044
48. Liu H, He Z, Simon HU. Targeting autophagy as a potential therapeutic approach for melanoma therapy. Semin Cancer Biol 2013; 23:352-60; PMID:23831275; http://dx.doi.org/10.1016/j.semcancer.2013.06.008
49. Fiorito F, Ciarcia R, Granato GE, Marfe G, Iovane V, Florio S, De Martino L, Pagnini U. 2,3,7,8-tetrachlorodibenzo- p-dioxin induced autophagy in a bovine kidney cell line. Toxicology 2011; 290:258-70; PMID:22015590; http://dx.doi.org/10.1016/j.tox.2011.10.004
50. Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3’-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 2000; 275:992-8; PMID:10625637; http://dx.doi.org/10.1074/jbc.275.2.992
51. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012; 4: a011189; PMID:22952397; http://dx.doi.org/10.1101/cshperspect.a011189
52. Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev of Pharmacol Toxicol 2013; 53:89-106; PMID:23294306; http://dx.doi.org/10.1146/annurev-pharmtox-010611-134717
53. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584:1287-95; PMID:20083114; http://dx.doi.org/10.1016/j.febslet.2010.01.017
54. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009; 122:3589-94; PMID:19812304; http://dx.doi.org/10.1242/jcs.051011
55. Bar-Peled L, Sabatini DM. Regulation of mTORC1 by amino acids. Trends Cell Biol 2014; 24:400-6; PMID:24698685; http://dx.doi.org/10.1016/j.tcb.2014.03.003
56. Jewell JL, Guan KL. Nutrient signaling to mTOR and cell growth. Trends Biochem Sci 2013; 38:233-42; PMID:23465396; http://dx.doi.org/10.1016/j.tibs.2013.01.004
57. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(C)-ATPase. Science 2011; 334:678-83; PMID:22053050; http://dx.doi.org/10.1126/science.1207056
58. Ma XM, Blenis J. Molecular mechanisms of mTORmediated translational control. Nat Rev Mol Cell Biol 2009; 10:307-18; PMID:19339977; http://dx.doi.org/10.1038/nrm2672
59. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res 2007; 17:666-81; PMID:17680028; http://dx.doi.org/10.1038/cr.2007.64
60. Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res 2010; 2:19-42; PMID:20182580
61. Nazio F, Strappazzon F, Antonioli M, Bielli P, Cianfanelli V, Bordi M, Gretzmeier C, Dengjel J, Piacentini M, Fimia GM, et al. mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat Cell Biol 2013; 15:406-16; PMID:23524951; http://dx.doi.org/10.1038/ncb2708
62. Zhou J, Tan SH, Nicolas V, Bauvy C, Yang ND, Zhang J, Xue Y, Codogno P, Shen HM. Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion. Cell Res 2013; 23:508-23; PMID:23337583; http://dx.doi.org/10.1038/cr.2013.11
63. Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, Huynh T, Ferron M, Karsenty G, Vellard MC, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J 2012; 31:1095-108; PMID:22343943; http://dx.doi.org/10.1038/emboj.2012.32
64. Roczniak-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B, Walther TC, Ferguson SM. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal 2012; 5:ra42; PMID:22692423; http://dx.doi.org/10.1126/scisignal.2002790
65. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011; 13:132-41; PMID:21258367; http://dx.doi.org/10.1038/ncb2152
66. Calnan DR, Brunet A. The FoxO code. Oncogene 2008; 27:2276-88; PMID:18391970; http://dx.doi.org/10.1038/onc.2008.21
67. Eijkelenboom A, Burgering BM. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol 2013; 14:83-97; PMID:23325358; http://dx.doi.org/10.1038/nrm3507
68. Yuan HX, Russell RC, Guan KL. Regulation of PIK3C3/VPS34 complexes by MTOR in nutrient stress-induced autophagy. Autophagy 2013; 9:1983-95; PMID:24013218; http://dx.doi.org/10.4161/auto.26058
69. Dou Z, Chattopadhyay M, Pan JA, Guerriero JL, Jiang YP, Ballou LM, Yue Z, Lin RZ, Zong WX. The class IA phosphatidylinositol 3-kinase p110-beta subunit is a positive regulator of autophagy. J Cell Biol 2010; 191:827-43; PMID:21059846; http://dx.doi.org/10.1083/jcb.201006056
70. Dou Z, Pan JA, Dbouk HA, Ballou LM, DeLeon JL, Fan Y, Chen JS, Liang Z, Li G, Backer JM, et al. Class IA PI3K p110beta subunit promotes autophagy through Rab5 small GTPase in response to growth factor limitation. Mol Cell 2013; 50:29-42; PMID:23434372; http://dx.doi.org/10.1016/j.molcel.2013.01.022
71. Murray JT, Panaretou C, Stenmark H, Miaczynska M, Backer JM. Role of Rab5 in the recruitment of hVps34/p150 to the early endosome. Traffic 2002; 3:416-27; PMID:12010460; http://dx.doi.org/10.1034/j.1600-0854.2002.30605.x
72. Blommaart EF, Krause U, Schellens JP, Vreeling-Sindelarova H, Meijer AJ. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem 1997; 243:240-6; PMID:9030745; http://dx.doi.org/10.1111/j.1432-1033.1997.0240a.x
73. Kiel JA, Rechinger KB, van der Klei IJ, Salomons FA, Titorenko VI, Veenhuis M. The Hansenula polymorpha PDD1 gene product, essential for the selective degradation of peroxisomes, is a homologue of Saccharomyces cerevisiae Vps34p. Yeast 1999; 15:741-54; PMID:10398343; http://dx.doi.org/10.1002/(SICI)1097-0061(19990630)15:9%3c741::AID-YEA416%3e3.0.CO;2-O
74. Kihara A, Noda T, Ishihara N, Ohsumi Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J Cell Biol 2001; 152:519-30; PMID:11157979; http://dx.doi.org/10.1083/jcb.152.3.519
75. Itakura E, Kishi C, Inoue K, Mizushima N. Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol Biol Cell 2008; 19:5360-72; PMID:18843052; http://dx.doi.org/10.1091/mbc.E08-01-0080
76. Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH, Jung JU. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol 2006; 8:688-99; PMID:16799551; http://dx.doi.org/10.1038/ncb1426
77. Zhong Y, Wang QJ, Li X, Yan Y, Backer JM, Chait BT, Heintz N, Yue Z. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol 2009; 11:468-76; PMID:19270693; http://dx.doi.org/10.1038/ncb1854
78. Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, Kurotori N, Maejima I, Shirahama-Noda K, Ichimura T, Isobe T, et al. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol 2009; 11:385-96; PMID:19270696; http://dx.doi.org/10.1038/ncb1846
79. Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di Bartolomeo S, Nardacci R, Corazzari M, Fuoco C, Ucar A, Schwartz P, et al. Ambra1 regulates autophagy and development of the nervous system. Nature 2007; 447:1121-5; PMID:17589504
80. Di Bartolomeo S, Corazzari M, Nazio F, Oliverio S, Lisi G, Antonioli M, Pagliarini V, Matteoni S, Fuoco C, Giunta L, et al. The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy. J Cell Biol 2010; 191:155-68; PMID:20921139; http://dx.doi.org/10.1083/jcb.201002100
81. Lu J, He L, Behrends C, Araki M, Araki K, Jun Wang Q, Catanzaro JM, Friedman SL, Zong WX, Fiel MI, et al. NRBF2 regulates autophagy and prevents liver injury by modulating Atg14L-linked phosphatidylinositol- 3 kinase III activity. Nat Commun 2014;5:3920; PMID:24849286
82. Zhong Y, Morris DH, Jin L, Patel MS, Karunakaran SK, Fu YJ, Matuszak EA, Weiss HL, Chait BT, Wang QJ. Nrbf2 protein suppresses autophagy by modulating Atg14L protein-containing Beclin 1-Vps34 complex architecture and reducing intracellular phosphatidylinositol-3 phosphate levels. J Biol Chem 2014; 289:26021-37; PMID:25086043; http://dx.doi.org/10.1074/jbc.M114.561134
83. Cao Y, Wang Y, Abi Saab WF, Yang F, Pessin JE, Backer JM. NRBF2 regulates macroautophagy as a component of Vps34 Complex I. Biochem J 2014; 461:315-22; PMID:24785657; http://dx.doi.org/10.1042/BJ20140515
84. Funderburk SF, Wang QJ, Yue Z. The Beclin 1-VPS34 complex–at the crossroads of autophagy and beyond. Trends Cell Biol 2010; 20:355-62; PMID:20356743; http://dx.doi.org/10.1016/j.tcb.2010.03.002
85. Fu LL, Cheng Y, Liu B. Beclin-1: autophagic regulator and therapeutic target in cancer. Int J Biochem Cell Biol 2013; 45:921-4; PMID:23420005; http://dx.doi.org/10.1016/j.biocel.2013.02.007
86. Liang C, Lee JS, Inn KS, Gack MU, Li Q, Roberts EA, Vergne I, Deretic V, Feng P, Akazawa C, et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. Nat Cell Biol 2008; 10:776-87; PMID:18552835; http://dx.doi.org/10.1038/ncb1740
87. Baskaran S, Carlson LA, Stjepanovic G, Young LN, Kim do J, Grob P, Stanley RE, Nogales E, Hurley JH. Architecture and dynamics of the autophagic phosphatidylinositol 3-kinase complex. ELife 2014; 3; PMID:25490155; http://dx.doi.org/10.7554/eLife.05115
88. Itakura E, Mizushima N. Atg14 and UVRAG: mutually exclusive subunits of mammalian Beclin 1-PI3K complexes. Autophagy 2009; 5:534-6; PMID: 19223761; http://dx.doi.org/10.4161/auto.5.4.8062
89. Thoresen SB, Pedersen NM, Liestol K, Stenmark H. A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. Exp Cell Res 2010; 316:3368-78; PMID:20643123; http://dx.doi.org/10.1016/j.yexcr.2010.07.008
90. Yan Y, Backer JM. Regulation of class III (Vps34) PI3Ks. Biochem Soc Trans 2007; 35:239-41; PMID:17371248; http://dx.doi.org/10.1042/BST0350242
91. Yan Y, Flinn RJ, Wu H, Schnur RS, Backer JM. hVps15, but not Ca2C/CaM, is required for the activity and regulation of hVps34 in mammalian cells. Biochem J 2009; 417:747-55; PMID:18957027; http://dx.doi.org/10.1042/BJ20081865
92. Stack JH, Herman PK, Schu PV, Emr SD. A membrane- associated complex containing the Vps15 protein kinase and the Vps34 PI 3-kinase is essential for protein sorting to the yeast lysosome-like vacuole. EMBO J 1993; 12:2195-204; PMID:8387919
93. Gillooly DJ, Morrow IC, Lindsay M, Gould R, Bryant NJ, Gaullier JM, Parton RG, Stenmark H. Localization of phosphatidylinositol 3-phosphate in yeast and mammalian cells. EMBO J 2000; 19:4577-88; PMID:10970851; http://dx.doi.org/10.1093/emboj/19.17.4577
94. Efe JA, Botelho RJ, Emr SD. Atg18 regulates organelle morphology and Fab1 kinase activity independent of its membrane recruitment by phosphatidylinositol 3,5-bisphosphate. Mol Biol Cell 2007; 18:4232-44; PMID:17699591; http://dx.doi.org/10.1091/mbc.E07-04-0301
95. Polson HE, de Lartigue J, Rigden DJ, Reedijk M, Urbe S, Clague MJ, Tooze SA. Mammalian Atg18 (WIPI2) localizes to omegasome-anchored phagophores and positively regulates LC3 lipidation. Autophagy 2010; 6:506-22; PMID:20505359; http://dx.doi.org/10.4161/auto.6.4.11863
96. Filimonenko M, Isakson P, Finley KD, Anderson M, Jeong H, Melia TJ, Bartlett BJ, Myers KM, Birkeland HC, Lamark T, et al. The selective macroautophagic degradation of aggregated proteins requires the PI3Pbinding protein Alfy. Mol Cell 2010; 38:265-79; PMID:20417604; http://dx.doi.org/10.1016/j.molcel.2010.04.007
97. Girardi JP, Pereira L, Bakovic M. De novo synthesis of phospholipids is coupled with autophagosome formation. Med Hypotheses 2011; 77:1083-7; PMID:21963355; http://dx.doi.org/10.1016/j.mehy.2011.09.008
98. Chen D, Fan W, Lu Y, Ding X, Chen S, Zhong Q. A mammalian autophagosome maturation mechanism mediated by TECPR1 and the Atg12-Atg5 conjugate. Mol Cell 2012; 45:629-41; PMID:22342342; http://dx.doi.org/10.1016/j.molcel.2011.12.036
99. Pankiv S, Alemu EA, Brech A, Bruun JA, Lamark T, Overvatn A, Bjorkoy G, Johansen T. FYCO1 is a Rab7 effector that binds to LC3 and PI3P to mediate microtubule plus end-directed vesicle transport. J Cell Biol 2010; 188:253-69; PMID:20100911; http://dx.doi.org/10.1083/jcb.200907015
100. Cheng J, Fujita A, Yamamoto H, Tatematsu T, Kakuta S, Obara K, Ohsumi Y, Fujimoto T. Yeast and mammalian autophagosomes exhibit distinct phosphatidylinositol 3-phosphate asymmetries. Nat Commun 2014; 5:3207;
101. PMID:24492518
102. Cebollero E, van der Vaart A, Zhao M, Rieter E, Klionsky DJ, Helms JB, Reggiori F. Phosphatidylinositol-3-phosphate clearance plays a key role in autophagosome completion. Curr Biol 2012; 22:1545-53; PMID:22771041; http://dx.doi.org/10.1016/j.cub.2012.06.029
103. Vergne I, Deretic V. The role of PI3P phosphatases in the regulation of autophagy. FEBS Lett 2010; 584:1313-8; PMID:20188094; http://dx.doi.org/10.1016/j.febslet.2010.02.054
104. Vergne I, Roberts E, Elmaoued RA, Tosch V, Delgado MA, Proikas-Cezanne T, Laporte J, Deretic V. Control of autophagy initiation by phosphoinositide 3-phosphatase Jumpy. EMBO J 2009; 28:2244-58; PMID:19590496; http://dx.doi.org/10.1038/emboj.2009.159
105. Dowling JJ, Low SE, Busta AS, Feldman EL. Zebrafish MTMR14 is required for excitation-contraction coupling, developmental motor function and the regulation of autophagy. Hum Mol Genet 2010; 19:2668-81; PMID:20400459; http://dx.doi.org/10.1093/hmg/ddq153
106. Taguchi-Atarashi N, Hamasaki M, Matsunaga K, Omori H, Ktistakis NT, Yoshimori T, Noda T. Modulation of local PtdIns3P levels by the PI phosphatase MTMR3 regulates constitutive autophagy. Traffic 2010; 11:468-78; PMID:20059746; http://dx.doi.org/10.1111/j.1600-0854.2010.01034.x
107. Vicinanza M, Korolchuk VI, Ashkenazi A, Puri C, Menzies FM, Clarke JH, Rubinsztein DC. PI(5)P regulates autophagosome biogenesis. Mol Cell 2015; 57:219-34; PMID:25578879; http://dx.doi.org/10.1016/j.molcel.2014.12.007
108. Mauthe M, Jacob A, Freiberger S, Hentschel K, Stierhof YD, Codogno P, Proikas-Cezanne T. Resveratrolmediated autophagy requires WIPI-1-regulated LC3 lipidation in the absence of induced phagophore formation. Autophagy 2011; 7:1448-61; PMID:22082875; http://dx.doi.org/10.4161/auto.7.12.17802
109. Scarlatti F, Maffei R, Beau I, Codogno P, Ghidoni R. Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ 2008; 15:1318-29; PMID:18421301; http://dx.doi.org/10.1038/cdd.2008.51
110. Zhu JH, Horbinski C, Guo F, Watkins S, Uchiyama Y, Chu CT. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am J Pathol 2007; 170:75-86; PMID:17200184; http://dx.doi.org/10.2353/ajpath.2007.060524
111. Zhou X, Takatoh J, Wang F. The mammalian class 3 PI3K (PIK3C3) is required for early embryogenesis and cell proliferation. PloS One 2011; 6:e16358
112. Jaber N, Dou Z, Chen JS, Catanzaro J, Jiang YP, Ballou LM, Selinger E, Ouyang X, Lin RZ, Zhang J, et al. Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proc Natl Acad Sci U S A 2012; 109:2003-8; PMID:22308354; http://dx.doi.org/10.1073/pnas.1112848109
113. Kim J, Kim YC, Fang C, Russell RC, Kim JH, Fan W, Liu R, Zhong Q, Guan KL. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell 2013; 152:290-303; PMID:23332761; http://dx.doi.org/10.1016/j.cell.2012.12.016
114. Furuya T, Kim M, Lipinski M, Li J, Kim D, Lu T, Shen Y, Rameh L, Yankner B, Tsai LH, et al. Negative regulation of Vps34 by Cdk mediated phosphorylation. Mol cell 2010; 38:500-11; PMID:20513426; http://dx.doi.org/10.1016/j.molcel.2010.05.009
115. Eisenberg-Lerner A, Kimchi A. PKD is a kinase of Vps34 that mediates ROS-induced autophagy downstream of DAPk. Cell Death Differ 2012; 19:788-97; PMID:22095288; http://dx.doi.org/10.1038/cdd.2011.149
116. Yang Y, Fiskus W, Yong B, Atadja P, Takahashi Y, Pandita TK, Wang HG, Bhalla KN. Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy. Proc Natl Acad Sci U S A 2013; 110:6841-6; PMID:23569248; http://dx.doi.org/10.1073/pnas.1217692110
117. Gulati P, Gaspers LD, Dann SG, Joaquin M, Nobukuni T, Natt F, Kozma SC, Thomas AP, Thomas G. Amino acids activate mTOR complex 1 via Ca2C/ CaM signaling to hVps34. Cell Metab 2008; 7:456-65; PMID:18460336; http://dx.doi.org/10.1016/j.cmet.2008.03.002
118. Byfield MP, Murray JT, Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 2005; 280:33076-82; PMID:16049009; http://dx.doi.org/10.1074/jbc.M507201200
119. Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P, Byfield MP, Backer JM, Natt F, Bos JL, et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A 2005; 102:14238-43; PMID:16176982; http://dx.doi.org/10.1073/pnas.0506925102
120. Ghislat G, Patron M, Rizzuto R, Knecht E. Withdrawal of essential amino acids increases autophagy by a pathway involving Ca2C/calmodulin-dependent kinase kinase-beta (CaMKK-beta). J Biol Chem 2012; 287:38625-36; PMID:23027865; http://dx.doi.org/10.1074/jbc.M112.365767
121. Russell RC, Tian Y, Yuan H, Park HW, Chang YY, Kim J, Kim H, Neufeld TP, Dillin A, Guan KL. ULK1 induces autophagy by phosphorylating Beclin- 1 and activating VPS34 lipid kinase. Nat Cell Biol 2013; 15:741-50; PMID:23685627; http://dx.doi.org/10.1038/ncb2757
122. Yu X, Long YC. Autophagy modulates amino acid signaling network in myotubes: differential effects on mTORC1 pathway and the integrated stress response. FASEB J 2015; 29:394-407; PMID:25376834; http://dx.doi.org/10.1096/fj.14-252841
123. Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, Mi N, Zhao Y, Liu Z, Wan F, et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 2010; 465:942-6; PMID:20526321; http://dx.doi.org/10.1038/nature09076
124. Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J 2008; 410:1-17; PMID:18215151; http://dx.doi.org/10.1042/BJ20071427
125. Li M, Khambu B, Zhang H, Kang JH, Chen X, Chen D, Vollmer L, Liu PQ, Vogt A, Yin XM. Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1(MTORC1) activity. J Biol Chem 2013; 288:35769-80; PMID:24174532; http://dx.doi.org/10.1074/jbc.M113.511212
126. Juhasz G, Hill JH, Yan Y, Sass M, Baehrecke EH, Backer JM, Neufeld TP. The class III PI(3)K Vps34 promotes autophagy and endocytosis but not TOR signaling in Drosophila. J Cell Biol 2008; 181:655-66; PMID:18474623; http://dx.doi.org/10.1083/jcb.200712051
127. Sahni S, Merlot AM, Krishan S, Jansson PJ, Richardson DR. Gene of the month: BECN1. J Clin Pathol 2014; 67:656-60; PMID:24811486; http://dx.doi.org/10.1136/jclinpath-2014-202356
128. Toton E, Lisiak N, Sawicka P, Rybczynska M. Beclin- 1 and its role as a target for anticancer therapy. J Physiol Pharmacol 2014; 65:459-67; PMID:25179078
129. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 2003; 100:15077-82; PMID:14657337; http://dx.doi.org/10.1073/pnas.2436255100
130. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112:1809-20; PMID:14638851; http://dx.doi.org/10.1172/JCI20039
131. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122:927-39; PMID:16179260; http://dx.doi.org/10.1016/j.cell.2005.07.002
132. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 2008; 30:678-88; PMID:18570871; http://dx.doi.org/10.1016/j.molcel.2008.06.001
133. Pimkina J, Humbey O, Zilfou JT, Jarnik M, Murphy ME. ARF induces autophagy by virtue of interaction with Bcl-xl. J Biol Chem 2009; 284:2803-10; PMID:19049976; http://dx.doi.org/10.1074/jbc.M804705200
134. Wang RC, Wei Y, An Z, Zou Z, Xiao G, Bhagat G, White M, Reichelt J, Levine B. Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science 2012; 338:956-9; PMID:23112296; http://dx.doi.org/10.1126/science.1225967
135. Zalckvar E, Berissi H, Mizrachy L, Idelchuk Y, Koren I, Eisenstein M, Sabanay H, Pinkas-Kramarski R, Kimchi A. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep 2009; 10:285-92; PMID:19180116; http://dx.doi.org/10.1038/embor.2008.246
136. Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 2013; 154:1269-84; PMID:24034250; http://dx.doi.org/10.1016/j.cell.2013.08.015
137. Abrahamsen H, Stenmark H, Platta HW. Ubiquitination and phosphorylation of Beclin 1 and its binding partners: tuning class III phosphatidylinositol 3-kinase activity and tumor suppression. FEBS Lett 2012; 586:1584-91; PMID:22673570; http://dx.doi.org/10.1016/j.febslet.2012.04.046
138. Reidick C, El Magraoui F, Meyer HE, Stenmark H, Platta HW. Regulation of the Tumor-Suppressor Function of the Class III Phosphatidylinositol 3- Kinase Complex by Ubiquitin and SUMO. Cancers 2014; 7:1-29; PMID:25545884; http://dx.doi.org/10.3390/cancers7010001
139. Platta HW, Abrahamsen H, Thoresen SB, Stenmark H. Nedd4-dependent lysine-11-linked polyubiquitination of the tumour suppressor Beclin 1. Biochem J 2012; 441:399-406; PMID:21936852; http://dx.doi.org/10.1042/BJ20111424
140. Xu C, Liu J, Hsu LC, Luo Y, Xiang R, Chuang TH. Functional interaction of heat shock protein 90 and Beclin 1 modulates Toll-like receptor-mediated autophagy. FASEB J 2011; 25:2700-10; PMID:21543763; http://dx.doi.org/10.1096/fj.10-167676
141. Shi CS, Kehrl JH. TRAF6 and A20 regulate lysine 63- linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. Sci Signal 2010; 3:ra42; PMID:20501938
142. He C, Levine B. The Beclin 1 interactome. Curr Opin Cell Biol 2010; 22:140-9; PMID:20097051; http://dx.doi.org/10.1016/j.ceb.2010.01.001
143. Matsunaga K, Morita E, Saitoh T, Akira S, Ktistakis NT, Izumi T, Noda T, Yoshimori T. Autophagy requires endoplasmic reticulum targeting of the PI3- kinase complex via Atg14L. J Cell Biol 2010; 190:511-21; PMID:20713597; http://dx.doi.org/10.1083/jcb.200911141
144. Pfisterer SG, Bakula D, Frickey T, Cezanne A, Brigger D, Tschan MP, Robenek H, Proikas-Cezanne T. Lipid droplet and early autophagosomal membrane targeting of Atg2A and Atg14L in human tumor cells. J Lipid Res 2014; 55:1267-78; PMID:24776541; http://dx.doi.org/10.1194/jlr.M046359
145. Obara K, Ohsumi Y. Atg14: a key player in orchestrating autophagy. Int J Cell Biol 2011; 2011:713435; PMID:22013444; http://dx.doi.org/10.1155/2011/713435
146. Fan W, Nassiri A, Zhong Q. Autophagosome targeting and membrane curvature sensing by Barkor/Atg14 (L). Proc Nat Acad Sci U S A 2011; 108:7769-74;PMID:21518905; http://dx.doi.org/10.1073/pnas.1016472108
147. Teitz T, Penner M, Eli D, Stark M, Bakhanashvili M, Naiman T, Canaani D. Isolation by polymerase chain reaction of a cDNA whose product partially complements the ultraviolet sensitivity of xeroderma pigmentosum group C cells. Gene 1990; 87:295-8;PMID:2332174; http://dx.doi.org/10.1016/0378-1119(90)90316-J
148. Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, Kelley PM, Pebusque MJ, Theillet C, Birnbaum D, et al. Detailed map of a region commonly amplified at 11q13–>q14 in human breast carcinoma. Cytogenet Cell Genet 1997; 79:125-31; PMID:9533029; http://dx.doi.org/10.1159/000134699
149. Goi T, Kawasaki M, Yamazaki T, Koneri K, Katayama K, Hirose K, Yamaguchi A. Ascending colon cancer with hepatic metastasis and cholecystolithiasis in a patient with situs inversus totalis without any expression of UVRAG mRNA: report of a case. Surg Today 2003; 33:702-6; PMID:12928850; http://dx.doi.org/10.1007/s00595-002-2567-y
150. Liang C, Feng P, Ku B, Oh BH, Jung JU. UVRAG: a new player in autophagy and tumor cell growth. Autophagy 2007; 3:69-71; PMID:17106237; http://dx.doi.org/10.4161/auto.3437
151. Ionov Y, Nowak N, Perucho M, Markowitz S, Cowell JK. Manipulation of nonsense mediated decay identifies gene mutations in colon cancer Cells with microsatellite instability. Oncogene 2004; 23:639-45; PMID:14737099; http://dx.doi.org/10.1038/sj.onc.1207178
152. Zhao Z, Oh S, Li D, Ni D, Pirooz SD, Lee JH, Yang S, Lee JY, Ghozalli I, Costanzo V, et al. A dual role for UVRAG in maintaining chromosomal stability independent of autophagy. Dev Cell 2012; 22:1001-16; PMID:22542840; http://dx.doi.org/10.1016/j.devcel.2011.12.027
153. Park JM, Tougeron D, Huang S, Okamoto K, Sinicrope FA. Beclin 1 and UVRAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cells. PloS One 2014; 9:e100819; PMID:24956373; http://dx.doi.org/10.1371/journal.pone.0100819
154. Zhao Z, Ni D, Ghozalli I, Pirooz SD, Ma B, Liang C. UVRAG: at the crossroad of autophagy and genomic stability. Autophagy 2012; 8:1392-3; PMID:22885520; http://dx.doi.org/10.4161/auto.21035
155. Song Z, An L, Ye Y, Wu J, Zou Y, He L, Zhu H. Essential role for UVRAG in autophagy and maintenance of cardiac function. Cardiovasc Res 2014; 101:48-56; PMID:24081163; http://dx.doi.org/10.1093/cvr/cvt223
156. Yang W, Ju JH, Lee KM, Nam K, Oh S, Shin I. Protein kinase B/Akt1 inhibits autophagy by down-regulating UVRAG expression. Exp Cell Res 2013; 319:122-33; PMID:23200933; http://dx.doi.org/10.1016/j.yexcr.2012.11.014
157. He S, Ni D, Ma B, Lee JH, Zhang T, Ghozalli I, Pirooz SD, Zhao Z, Bharatham N, Li B, et al. PtdIns(3) P-bound UVRAG coordinates Golgi-ER retrograde and Atg9 transport by differential interactions with the ER tether and the beclin 1 complex. Nat Cell Biol 2013; 15:1206-19; PMID:24056303; http://dx.doi.org/10.1038/ncb2848
158. Lorincz P, Lakatos Z, Maruzs T, Szatmari Z, Kis V, Sass M. Atg6/UVRAG/Vps34-containing lipid kinase complex is required for receptor downregulation through endolysosomal degradation and epithelial polarity during Drosophila wing development. BioMed Res Int 2014; 2014:851349; PMID:25006588; http://dx.doi.org/10.1155/2014/851349
159. Knaevelsrud H, Ahlquist T, Merok MA, Nesbakken A, Stenmark H, Lothe RA, Simonsen A. UVRAG mutations associated with microsatellite unstable colon cancer do not affect autophagy. Autophagy 2010; 6:863-70; PMID:20724836; http://dx.doi.org/10.4161/auto.6.7.13033
160. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature 2010; 466:68-76; PMID:20562859; http://dx.doi.org/10.1038/nature09204
161. Araki Y, Ku WC, Akioka M, May AI, Hayashi Y, Arisaka F, Ishihama Y, Ohsumi Y. Atg38 is required for autophagy-specific phosphatidylinositol 3-kinase complex integrity. J Cell Biol 2013; 203:299-313; PMID:24165940; http://dx.doi.org/10.1083/jcb.201304123
162. Falasca M, Maffucci T. Role of class II phosphoinositide 3-kinase in cell signalling. Biochem Soc Trans 2007; 35:211-4; PMID:17371240; http://dx.doi.org/10.1042/BST0350229
163. Arcaro A, Zvelebil MJ, Wallasch C, Ullrich A, Waterfield MD, Domin J. Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mole Cell Biol 2000; 20:3817-30; PMID:10805725; http://dx.doi.org/10.1128/MCB.20.11.3817-3830.2000
164. Maffucci T, Cooke FT, Foster FM, Traer CJ, Fry MJ, Falasca M. Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol 2005; 169:789-99; PMID:15928202; http://dx.doi.org/10.1083/jcb.200408005
165. Biswas K, Yoshioka K, Asanuma K, Okamoto Y, Takuwa N, Sasaki T, Takuwa Y. Essential role of class II phosphatidylinositol-3-kinase-C2alpha in sphingosine 1-phosphate receptor-1-mediated signaling and migration in endothelial cells. J Biol Chem 2013;288:2325-39; PMID:23192342; http://dx.doi.org/10.1074/jbc.M112.409656
166. Wen PJ, Osborne SL, Morrow IC, Parton RG, Domin J, Meunier FA. Ca2C-regulated pool of phosphatidylinositol- 3-phosphate produced by phosphatidylinositol 3-kinase C2alpha on neurosecretory vesicles. Mol Biol Cell 2008; 19:5593-603; PMID:18843041; http://dx.doi.org/10.1091/mbc.E08-06-0595
167. Traer CJ, Foster FM, Abraham SM, Fry MJ. Are class II phosphoinositide 3-kinases potential targets for anticancer therapies? Bull Cancer 2006; 93:E53-8;PMID:16777618
168. Lu N, Shen Q, Mahoney TR, Neukomm LJ, Wang Y, Zhou Z. Two PI 3-kinases and one PI 3-phosphatase together establish the cyclic waves of phagosomal PtdIns(3)P critical for the degradation of apoptotic cells. PLoS Biol 2012; 10:e1001245; PMID:22272187; http://dx.doi.org/10.1371/journal.pbio.1001245
169. Cheng S, Wu Y, Lu Q, Yan J, Zhang H, Wang X. Autophagy genes coordinate with the class II PI/PtdIns 3-kinase PIKI-1 to regulate apoptotic cell clearance in C. elegans. Autophagy 2013; 9:2022-32; PMID:24165672; http://dx.doi.org/10.4161/auto.26323
170. Bechtel W, Helmstadter M, Balica J, Hartleben B, Kiefer B, Hrnjic F, Schell C, Kretz O, Liu S, Geist F, et al. Vps34 deficiency reveals the importance of endocytosis for podocyte homeostasis. J Am Soc Nephrol 2013; 24:727-43; PMID:23492732; http://dx.doi.org/10.1681/ASN.2012070700
171. Parekh VV, Wu L, Boyd KL, Williams JA, Gaddy JA, Olivares-Villagomez D, Cover TL, Zong WX, Zhang J, Van Kaer L. Impaired autophagy, defective T cell homeostasis, and a wasting syndrome in mice with a T cell-specific deletion of Vps34. J Immunol 2013; 190:5086-101; http://dx.doi.org/10.4049/jimmunol.1202071
172. Devereaux K, Dall’Armi C, Alcazar-Roman A, Ogasawara Y, Zhou X, Wang F, Yamamoto A, De Camilli P, Di Paolo G. Regulation of mammalian autophagy by class II and III PI 3-kinases through PI3P synthesis. PloS One 2013; 8:e76405; PMID:24098492; http://dx.doi.org/10.1371/journal.pone.0076405
173. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013; 10:143-53; PMID:23400000; http://dx.doi.org/10.1038/nrclinonc.2013.10
174. Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012; 10:161; PMID:23232172; http://dx.doi.org/10.1186/1741-7015-10-161
175. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-62; PMID:19629070; http://dx.doi.org/10.1038/nrc2664
176. Martini M, Ciraolo E, Gulluni F, Hirsch E. Targeting PI3K in cancer: any good news? Front Oncol 2013; 3:108; PMID:23658859; http://dx.doi.org/10.3389/fonc.2013.00108
177. Eisenreich A, Rauch U. PI3K inhibitors in cardiovascular disease. Cardiovasc Ther 2011; 29:29-36; PMID:20626398; http://dx.doi.org/10.1111/j.1755-5922.2010.00206.x
178. Cleary JM, Shapiro GI. Development of phosphoinositide- 3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep 2010; 12:87-94; PMID:20425592; http://dx.doi.org/10.1007/s11912-010-0091-6
179. Yang YP, Hu LF, Zheng HF, Mao CJ, Hu WD, Xiong KP, Wang F, Liu CF. Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin 2013; 34:625-35; PMID:23524572; http://dx.doi.org/10.1038/aps.2013.5
180. Seglen PO, Gordon PB. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Nat Acad Sci U S A 1982; 79:1889-92; PMID:6952238; http://dx.doi.org/10.1073/pnas.79.6.1889
181. Xing C, Zhu B, Liu H, Yao H, Zhang L. Class I phosphatidylinositol 3-kinase inhibitor LY294002 activates autophagy and induces apoptosis through p53 pathway in gastric cancer cell line SGC7901. Acta Biochim Biophys Sin 2008; 40:194-201; PMID:18330473; http://dx.doi.org/10.1111/j.1745-7270.2008.00393.x
182. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, Ong CN, Codogno P, Shen HM. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 2010; 285:10850-61; PMID:20123989; http://dx.doi.org/10.1074/jbc.M109.080796
183. Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 2012; 23:2399-408; PMID:22357447; http://dx.doi.org/10.1093/annonc/mds011
184. Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, Bachelot MF, Lamberton A, Mathieu M, Bertrand T, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol 2014; 10:1013-9; PMID:25326666; http://dx.doi.org/10.1038/nchembio.1681
185. Bago R, Malik N, Munson MJ, Prescott AR, Davies P, Sommer E, Shpiro N, Ward R, Cross D, Ganley IG, et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3- kinase. Biochem J 2014; 463:413-27; PMID:25177796; http://dx.doi.org/10.1042/BJ20140889
186. Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, Menon S, Wang Z, Honda A, Pardee G, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol 2014; 16:1069-79; PMID:25327288; http://dx.doi.org/10.1038/ncb3053
187. Pasquier B, El-Ahmad Y, Filoche-Romme B, Dureuil C, Fassy F, Abecassis PY, Mathieu M, Bertrand T, Benard T, Barriere C, et al. Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)- 3,4-dihydro-2H-pyrimido [1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. J Med Chem 2015; 58:376-400; PMID:25402320; http://dx.doi.org/10.1021/jm5013352
188. Miller S, Tavshanjian B, Oleksy A, Perisic O, Houseman BT, Shokat KM, Williams RL. Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science 2010; 327:1638-42; PMID:20339072; http://dx.doi.org/10.1126/science.1184429
189. El-Said OM, Hamed MM, Laufer S, Abadi AH. Design and synthesis of novel quinazoline derivatives and their evaluation as PI3Ks inhibitors. Chem Pharm Bull 2014; 62:1166-72; PMID:25450624; http://dx.doi.org/10.1248/cpb.c14-00560
190. Freitag A, Prajwal P, Shymanets A, Harteneck C, Nurnberg B, Schachtele C, Kubbutat M, Totzke F, Laufer SA. Development of first lead structures for phosphoinositide 3-kinase-C2gamma inhibitors. J Med Chem 2015; 58:212-21; PMID:24983663; http://dx.doi.org/10.1021/jm5006034
191. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Bioch Biophys Acta 2008; 1784:159-85; PMID:17997386; http://dx.doi.org/10.1016/j.bbapap.2007.10.003
192. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G, et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3- kinase. Cancer Res 1994; 54:2419-23; PMID:8162590
193. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD, Panayotou G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996; 16:1722-33; PMID:8657148
194. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)- 8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269:5241-8; PMID:8106507
195. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008; 68:206-15; PMID:18172313; http://dx.doi.org/10.1158/0008-5472.CAN-07-0669
196. Chiorean EG, Mahadevan D, Harris WB, Von Hoff DD, Younger AE, Rensvold DM, Shelton CF, Hennessy BT, Garlich JR, Ramanathan RK. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol 2009; 48(18):3319-27; PMID:22921184
197. Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F, et al. Phase I pharmacokinetic and pharmacodynamic study of the pan- PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer 2012; 48:3319-27; PMID:22921184; http://dx.doi.org/10.1016/j.ejca.2012.06.027
198. Schwertschlag US, Chiorean EG, Anthony SP, Sweeney CJ, Borad MJ, Von Hoff DD, Garlich JR, Shelton CF, Ramanathan RK. Phase 1 pharmacokinetic (PK) and pharmacodynamic(PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3-kinase (PI3K) inhibitor in patients with solid tumors. J Clin Oncol 2008; 26
199. Mahadevan D, Chiorean EG, Harris W, Von Hoff DD, Younger A, Rensvold DM, Cordova F, Qi W, Shelton CF, Becker MD, et al. Phase I study of the multikinase prodrug SF1126 in solid tumors and Bcell malignancies. J Clin Oncol 2011; 29(14):1876-84; PMID:21483007; http://dx.doi.org/10.1200/JCO.2010.32.7171
200. Garlich JR, Becker MD, Shelton CF, Qi WQ, Liu XB, Cooke L, Mahadevan D. Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In BCel lMalignancies. Blood 2010; 116:744
201. Lonial S, Harvey RD, Francis D, Gul E, Jagannath S, Farag S, Hoth D, Frumento R, Garlich JR, Trudel S. Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma. Blood 2009; 114:1492-3; http://dx.doi.org/10.1182/blood-2009-04-217281
202. Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules 2014; 19:14304-15; PMID:25215588; http://dx.doi.org/10.3390/molecules190914304
203. Jimeno A, Shirai K, Choi M, Laskin J, Kochenderfer M, Spira A, Cline-Burkhardt V, Winquist E, Hausman D, Walker L, et al.. A randomized, phase 2 trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase Inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Ann Oncol 2014; 26:556-561; PMID:25524478; http://dx.doi.org/10.1093/annonc/mdu574.
204. Levy B, Spira A, Becker D, Evans T, Schnadig I,Camidge DR, Bauman JE, Hausman D, Walker L, Nemunaitis J, et al. A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. J Thorac Oncol 2014; 9:1031-5; PMID:24926548; http://dx.doi.org/10.1097/JTO.0000000000000183
205. Bowles DW, Senzer N, Hausman D, Peterson S, Vo A, Walker L, Cohen RB, Jimeno A. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2014; 32:1197-203; PMID:24916771; http://dx.doi.org/10.1007/s10637-014-0124-3
206. Bowles DW, Ma WW, Senzer N, Brahmer JR, Adjei AA, Davies M, Lazar AJ, Vo A, Peterson S, Walker L, et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer 2013; 109:1085-92; PMID:23942080; http://dx.doi.org/10.1038/bjc.2013.474
207. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O’Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012; 18:4173-82;PMID:22693357; http://dx.doi.org/10.1158/1078-0432.CCR-12-0714
208. Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004; 3:763-72; PMID:15252137
209. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. 5-866, against human glioblastoma. Neuro Oncol 2010; 12:559-69; PMID:20156803; http://dx.doi.org/10.1093/neuonc/nop058
210. Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, et al. Phase II study of PX- 866 in recurrent glioblastoma. Neuro-oncology 2015; PMID:25605819; http://dx.doi.org/10.1093/neuonc/nou365.
211. Hotte SJ, Eisenhauer EA, Joshua AM, Kumar V, Ellard S, Gregg RW, Macfarlane RJ, Winquist E, Torri V, Ruether JD, et al. NCIC CTG, IND-205: a phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2013; 31
212. Jimeno A, Herbst RS, Falchook GS, Messersmith WA, Hecker S, Peterson S, Hausman DF, Kurzrock R, Eckhardt SG, Hong DS. Final results from aphase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. J Clin Oncol 2010; 28
213. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Brana I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014; 20:233-45; PMID:24166903; http://dx.doi.org/10.1158/1078-0432.CCR-13-1777
214. Traynor AM, Kurzrock R, Bailey HH, Attia S, Scheffold C, van Leeuwen B, Wu B, Falchook GS, Moulder SL, Wheler J. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. J Clin Oncol 2010; 28
215. Moldovan C, Soria J, LoRusso P, Guthrie T, Song C, Nguyen LT, Martini J, Infante JR, Burris HA. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors. J Clin Oncol 2010; 28
216. Shapiro G, Kwak E, Baselga J, Rodon J, Scheffold C, Laird AD, Bedell C, Edelman G. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol 2009; 27
217. Edelman G, Bedell C, Shapiro G, Pandya SS, Kwak EL, Scheffold C, Nguyen LT, Laird A, Baselga J, Rodon J. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010; 28:2191-7; PMID:20351329
218. Calvo E, Edelman G, Baselga J, Kwak E, Scheffold C, Nguyen L, Shapiro GI. A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors. Ejc Suppl 2008; 6:69; http://dx.doi.org/10.1016/S1359-6349(08)72150-5
219. Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncology 2015; 136:246-53; PMID:25528496; http://dx.doi.org/10.1016/j.ygyno.2014.12.019
220. Corcelle EA, Puustinen P, Jaattela M. Apoptosis and autophagy: targeting autophagy signalling in cancer cells -’trick or treats’? FEBS J 2009; 276:6084-96; PMID:19788415; http://dx.doi.org/10.1111/j.1742-4658.2009.07332.x
221. Burger MT, Pecchi S, Wagman A, Ni ZJ, Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y, Bartulis S, et al. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett 2011; 2:774-9; PMID:24900266; http://dx.doi.org/10.1021/ml200156t
222. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30:282-90; PMID:22162589; http://dx.doi.org/10.1200/JCO.2011.36.1360
223. Rodon J, Brana I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014; 32:670-81; PMID:24652201
224. Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Perez-Garcia J, Stathis A, Britten CD, et al.. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res 2015; 21:730-8; PMID:25500057; http://dx.doi.org/10.1158/1078-0432.CCR-14-1814.
225. Zang C, Eucker J, Liu H, Coordes A, Lenarz M, Possinger K, Scholz CW. Inhibition of pan-class I phosphatidyl- inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55:425-34; PMID:23721513; http://dx.doi.org/10.3109/10428194.2013.806800
226. Patnaik A, Ramanathan RK, Dubowy R, Tolcher AW, Papadopoulos KP, Beeram M, Mountz JM, Rasco D, Lotze MT, Laymon C, et al. The evolution of Pi3 kinase inhibitors: results of a first-in-human phase I study of Bay80-6946 in advanced solid tumors. Ann Oncol 2012; 23:16; http://dx.doi.org/10.1093/annonc/mds439
227. Glienke W, Maute L, Wicht J, Bergmann L. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tum Biol 2012; 33:757-65; PMID:22170433; http://dx.doi.org/10.1007/s13277-011-0290-2
228. Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res 2011; 17:7116-26; PMID:21976531; http://dx.doi.org/10.1158/1078-0432.CCR-11-0796
229. Ahnert JR, Burris HA, Schellens JHM, Schuler M, Goodman O, Britten C, Richards D, Demanse D, Silva A, Baselga J. Phase I dose-escalation study of the oral dual MTOR/PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet formulation, in patients with advanced solid tumors. Eur J Cancer 2012; 48:112; http://dx.doi.org/10.1016/S0959-8049(12)72164-0
230. Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante JR, Silva A, Demanse D, Hackl W, Baselga J. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 2010; 28
231. Dirix L, Schuler M, Machiels J, Hess D, Awada A, Steeghs N, Paz-Ares L, von Moos R, Rabault B, Rodon J. Phase Ib dose-escalation study of Bez235 or Bkm120 in combination with paclitaxel (Ptx) in patients with advanced solid tumors. Ann Oncol 2012; 23:157-8
232. Krop IE, Saura C, Ahnert JR, Becerra C, Britten CD, Isakoff SJ, Demanse D, Hackl W, Quadt C, Silva AP, et al. A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2Cmetastatic breast cancer. J Clin Oncol 2012; 30
233. Salkeni MA, Beg MS, Olowokure OO, Fathallah H, Thomas H, Mercer CA, Charif M, Chaudhary RT, Karim NA, Warnick R, et al. A dose escalation, single arm, phase Ib/II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics, and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme. J Clin Oncol 2012; 30
234. Seitz C, Hugle M, Cristofanon S, Tchoghandjian A, Fulda S. The dual PI3K/mTOR inhibitor NVPBEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. Int J Cancer 2013; 132:2682-93; PMID:23151917; http://dx.doi.org/10.1002/ijc.27935
235. Janne PA, Cohen RB, Laird AD, Mace S, Engelman JA, Ruiz-Soto R, Rockich K, Xu J, Shapiro GI, Martinez P, et al. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J Thoracic Oncol 2014; 9:316-23; PMID:24496004; http://dx.doi.org/10.1097/JTO.0000000000000088
236. Papadopoulos KP, Tabernero J, Markman B, Patnaik A, Tolcher AW, Baselga J, Shi W, Egile C, Ruiz-Soto R, Laird AD, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res 2014; 20:2445-56; PMID:24583798; http://dx.doi.org/10.1158/1078-0432.CCR-13-2403
237. LoRusso P, Markman B, Tabernero J, Shazer R, Nguyen L, Heath E, Patnaik A, Papadopoulos K. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. J Clin Oncol 2009; 27
238. Markman B, LoRusso PM, Patnaik A, Heath E, Laird AD, van Leeuwen B, Papadopoulos KP, Baselga J. A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors. Ejc Suppl 2008; 6:68-9; http://dx.doi.org/10.1016/S1359-6349(08)72148-7
239. Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J, Brewer KJ, Hoffman A, Lusby K, Lazar AJ, et al. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther 2012; 11:1758-69; PMID:22848094; http://dx.doi.org/10.1158/1535-7163.MCT-12-0015
240. Flinn IW, Horwitz SM, Patel M, Younes A, Porter JR, Sweeney J, Allen K, Kelly P, Kahl BS. Clinical safety and activity in a phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-delta,gamma, in patients with advanced hematologic malignancies. Blood 2012; 120 PMID:23524572; http://dx.doi.org/10.1038/aps.2013.5
241. Sarker D, Kristeleit R, Mazina KE, Ware JA, Yan Y, Dresser M, Derynck MK, De-Bono J. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol 2009; 27
242. Baird RD, Kristeleit RS, Sarker D, Olmos D, Sandhu SK, Yan Y, Koeppen H, Levy GG, Jin J, De Bono JS. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide- 3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol 2010; 28
243. Baird R, Kristeleit R, Sarker D, Olmos D, Sandhu S, Levy GG, Mazina KE, Yan Y, Ware J, De Bono J. A phase I study evaluating the pharmacokinetics (Pk) and pharmacodynamics (Pd) of the oral pan-phosphoinositide- 3 kinase (Pi3k) inhibitor Gdc-0941. Ann Oncol 2010; 21:170-1
244. LoRusso P, Sarker D, Von Hoff D, Tibes R, Derynck MK, Ware JA, Yan Y, Demetri GD, de Bono JS, Wagner AJ. Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: initial phase I evaluation. Ejc Suppl 2008; 6:70-1; http://dx.doi.org/10.1016/S1359-6349(08)72155-4
245. Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol- 3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2015; 21:77-86; PMID:25370471; http://dx.doi.org/10.1158/1078-0432.CCR-14-0947
246. de Vos S, Schreeder MT, Flinn IW, Coutre SE, Leonard JP, Wagner-Johnston ND, Fowler NH, Boccia RV, Barrientos JC, Boyd T, et al. A Phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3K delta) inhibitor, Cal-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with previously treated, indolent non-hodgkin lymphoma (iNHL). Blood 2011; 118:1160
247. De Vos S, Sehn LH, Mulligan SP, Dreyling MH, Rummel MJ, Zinzani PL, Johnson DM, Evans S, Dansey RD, Godfrey WR, et al. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). J Clin Oncol 2013; 31
248. Eradat HA, Coutre SE, Barrientos JC, Rai KR, Farber CM, Hillmen P, Sharman JP, Ghia P, Coiffier B, Walewski JA, et al. A phase III, randomized, doubleblind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol 2013; 31
249. Flinn I, Kimby E, Cotter FE, Giles FJ, Janssens A, Pulczynski EJ, Ysebeart L, Pluta A, Marco JAG, Taylor K, et al. A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS- 1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol 2013; 31
250. Furman RR, Barrientos JC, Sharman JP, De Vos S, Leonard J, Coutre SE, Schreeder MT, Wagner- Johnston ND, Boyd TE, Fowler NH, et al. A phase I/II study of the selective phosphatidylinositol 3-kinase -delta (PI3K delta) inhibitor, GS- 1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol 2012; 30; PMID:22547602
251. O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Holes L, Johnson DM, Gu J, Dansey RD, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) >D 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol 2013; 31
252. Sharman J, de Vos S, Leonard JP, Furman RR, Coutre SE, Flinn IW, Schreeder MT, Barrientos JC, Wagner- Johnston ND, Boyd T, et al. A Phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3K delta) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2011; 118:779-80